T-small cell disorders
Tóm tắt
A minority (less than 2%) of all lymphoproliferative disorders are derived from small T cells. These include T-cell prolymphocytic leukemia, T-cell granular lymphocytic leukemia, and mycosis fungoides/Sézary syndrome. With the possible exception of early-stage, skin-localized mycosis fungoides, all are considered incurable, although palliation can be achieved with radiation therapy, chemotherapy, biologic therapy, and combinations of these modalities. Of these disorders, mycosis fungoides is the most common; it follows an indolent, though gradually progressive, course that spans years. The T-cell prolymphocytic leukemias, in contrast, are generally refractory to treatment, with a median survival of typically less than 1 year. Although effective therapy remains elusive in most cases, the development of nucleosides as a class of chemotherapeutic agents and biologics, including interferon, monoclonal antibodies, and vitamin A derivatives, offers new hope for at least more effective palliation of these progressive lymphoproliferative disorders. However, rapid improvement in the treatment of these disorders remains hampered by the rarity of these individual entities. More rapid progress in treatment depends on national and international cooperation to accrue patients for definitive trials of sufficient size to evaluate new treatment options quickly.
Tài liệu tham khảo
Rabkin CS, Devesa SS, Zahm SH, et al.: Increasing incidence of non-Hodgkin’s lymphoma. Semin Hematol 1993, 30:286–296.
Pearce N, Bethwaite P: Increasing incidence of non-Hodgkin’s lymphoma: occupational and environmental factors. Cancer Res 1992, 52:5496s-5500s.
National Cancer Institute: Sponsored study of classifications of non-Hodgkin’s lymphomas. Summary and description of a working formulation for clinical usage. The Non-Hodgkin’s Lymphoma Pathologic Classification Project. Cancer 1982, 49:2112–2135.
Lennert K, Stein H, Kaiserling E: Cytological and functional criteria for the classification of malignant lymphomata. Br J Cancer 1975, 31(suppl):29–43.
Harris NL, Jaffe ES, Stein H, et al.: A revised European-American classification of lymphoid neoplasms: a proposal from the International Lymphoma Study Group. Blood 1994, 84:1361–1392.
Harris NL, Jaffe ES, Diebold J, et al.: The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999, 10:1419–1432. This work summarizes the current classification scheme for all neoplastic diseases of hematopoietic and lymphoid origin, including the T-small cell disorders.
Jaffe ES, Harris NL, Diebold J, et al.: World Health Organization Classification of lymphomas: a work in progress. Ann Oncol 1998, 9(suppl):S25-S30.
Alizadeh AA, Eisen MB, Davis RE, et al.: Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000, 403:503–511.
Matutes E, Brito-Babapulle V, Swansbury J, et al.:Clinical and laboratory features of 78 cases of T-prolymphocytic leukemia. Blood 1991, 78:3269–3274.
Matutes E, Garcia M, Talavera J, et al.: The morphological spectrum of T-prolymphocytic leukaemia. Br J Haematol 1986, 64:111–124.
van’t Veer MB: Chromosome 14: a breakpoint in non-Hodgkin’s lymphomas. Neth J Med 1990, 37:37–43.
Gritti C, Dastot H, Soulier J, et al.: Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. Blood 1998, 92:368–373.
Butturini A, Gale RP: Oncogenes in chronic lymphocytic leukemia. Leuk Res 1988, 12:89–92.
Dohner H, Ho AD, Thaler J, et al.: Pentostatin in prolymphocytic leukemia: phase II trial of the European Organization for Research and Treatment of Cancer Leukemia Cooperative Study Group. J Natl Cancer Inst 1993, 85:658–662. One of the largest studies reporting treatment of prolymphocytic leukemias with pentostatin.
Palomera L, Domingo JM, Agullo JA, et al.: Complete remission in T-cell prolymphocytic leukemia with 2-chlorodeoxyadenosine. J Clin Oncol 1995, 13:1284–1285. This is not only a report of a treatment study, it is an excellent review of the use of purine analogs in T-cell prolymphocytic leukemia.
Dighiero G, Lim A, Lembezat MP, et al.: Comparative study of VH gene family usage by newborn xid and non-xid mice, newborn NZB and adult NZB mice, and by splenic and peritoneal cavity B cell compartments. Eur J Immunol 1988, 18:1979–1983.
Pawson R, Dyer MJ, Barge R, et al.: Treatment of T-cell prolymphocytic leukemia with human CD52 antibody. J Clin Oncol 1997, 15:2667–2672.
Bazarbachi A, Soriano V, Pawson R, et al.: Mycosis fungoides and Sézary syndrome are not associated with HTLV-I infection: an international study. Br J Haematol 1997, 98:927–933.
Semenzato G, Zambello R, Starkebaum G, et al.:The lymphoproliferative disease of granular lymphocytes: updated criteria for diagnosis. Blood 1997, 89:256–260.
Loughran TP Jr: Clonal diseases of large granular lymphocytes. Blood 1993, 82:1–14.
Dhodapkar MV, Lust JA, Phyliky RL: T-cell large granular lymphocytic leukemia and pure red cell aplasia in a patient with type I autoimmune polyendocrinopathy: response to immunosuppressive therapy. Mayo Clin Proc 1994, 69:1085–1088.
Kingreen D, Siegert W: Chronic lymphatic leukemias of T and NK cell type. Leukemia 1997, 11(suppl):S46-S49.
Dhodapkar MV, Li CY, Lust JA, et al.: Clinical spectrum of clonal proliferations of T-large granular lymphocytes: a T-cell clonopathy of undetermined significance? Blood 1994, 84:1620–1627.
Loughran TP Jr, Kidd PG, Starkebaum G: Treatment of large granular lymphocyte leukemia with oral low-dose methotrexate. Blood 1994, 84:2164–2170.
Sood R, Stewart CC, Aplan PD, et al.: Neutropenia associated with T-cell large granular lymphocyte leukemia: long-term response to cyclosporine therapy despite persistence of abnormal cells. Blood 1998, 91:3372–3378.
Tefferi A, Lacy MQ, Kurtin PJ: Response: pure red blood cell aplasia: association with large granular lymphocyte leukemia and the prognostic value of cytogenetic abnormalities. Blood 1996, 88:3245–3246.
Beljaards RC, Meijer CJ, Scheffer E, et al.: Cutaneous large cell lymphomas of T cell origin: diagnosis, classification and prognostic parameters. Curr Probl Dermatol 1990, 19:144–149.
Kim YH, Hoppe RT: Mycosis fungoides and the Sézary syndrome. Semin Oncol 1999, 26:276–289.
Zackheim HS, Vonderheid EC, Ramsay DL, et al.: Relative frequency of various forms of primary cutaneous lymphomas. J Am Acad Dermatol 2000, 43:793–796.
Morales Suarez-Varela MM, Llopis GA, Marquina VA, et al.: Mycosis fungoides: review of epidemiological observations. Dermatology 2000, 201:21–28.
Diamandidou E, Cohen PR, Kurzrock R: Mycosis fungoides and Sézary syndrome. Blood 1996, 88:2385–2409.
Santucci M, Biggeri A, Feller AC, et al.: Efficacy of histologic criteria for diagnosing early mycosis fungoides: an EORTC cutaneous lymphoma study group investigation. European Organization for Research and Treatment of Cancer. Am J Surg Pathol 2000, 24:40–50. This is one of the largest cooperative reviews of efficacy of criteria used in the diagnosis of mycosis fungoides.
Izban KF, Hsi ED, Alkan S: Immunohistochemical analysis of mycosis fungoides on paraffin-embedded tissue sections. Mod Pathol 1998, 11:978–982.
Howard MS, Smoller BR: Mycosis fungoides: classic disease and variant presentations. Semin Cutan Med Surg 2000, 19:91–99.
Kim YH, Hoppe RT: Mycosis fungoides and the Sézary syndrome. Semin Oncol 1999, 26:276–289.
Kern DE, Kidd PG, Moe R, et al.: Analysis of T-cell receptor gene rearrangement in lymph nodes of patients with mycosis fungoides. Prognostic implications. Arch Dermatol 1998, 134:158–164.
Van der Putte SC, Toonstra J, van Prooyen HC, et al.:Sézary syndrome with early immunoblastic transformation. Arch Dermatol Res 1984, 276:17–26.
Dmitrovsky E, Matthews MJ, Bunn PA, et al.: Cytologic transformation in cutaneous T cell lymphoma: a clinicopathologic entity associated with poor prognosis. J Clin Oncol 1987, 5:208–215.
Salhany KE, Cousar JB, Greer JP, et al.: Transformation of cutaneous T cell lymphoma to large cell lymphoma. A clinicopathologic and immunologic study. Am J Pathol 1988, 132:265–277.
Cerroni L, Rieger E, Hodl S, et al.: Clinicopathologic and immunologic features associated with transformation of mycosis fungoides to large-cell lymphoma. Am J Surg Pathol 1992, 16:543–552.
Matutes E, Schulz T, Dyer M, et al.: Immunoblastic transformation of a Sézary syndrome in a black Caribbean patient without evidence of HTLV-I. Leuk Lymph 1995, 18:521–527.
Vergier B, de Muret A, Beylot-Barry M, et al.: Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneous Lymphomas. Blood 2000, 95:2212–2218.
Abel EA, Wood GS, Hoppe RT: Mycosis fungoides: clinical and histologic features, staging, evaluation, and approach to treatment. CA Cancer J Clin 1993, 43:93–115.
Hoppe RT, Wood GS, Abel EA: Mycosis fungoides and the Sézary syndrome: pathology, staging, and treatment. Curr Probl Cancer 1990, 14:293–371.
Jones GW, Hoppe RT, Glatstein E: Electron beam treatment for cutaneous T-cell lymphoma. Hematol Oncol Clin North Am 1995, 9:1057–1076.
Kim YH, Jensen RA, Watanabe GL, et al.: Clinical stage IA (limited patch and plaque) mycosis fungoides. A long-term outcome analysis. Arch Dermatol 1996, 132:1309–1313. This is a critical review of long-term experience in the treatment of limited stage mycosis fungoides with a variety of treatment modalities.
Wood GS, Dubiel C, Mueller C, et al.: Most CD8+ cells in skin lesions of CD3+ CD4+ mycosis fungoides are CD3+ T cells that lack CD11b, CD16, CD56, CD57, and human Hanukah factor mRNA. Am J Pathol 1991, 138:1545–1552.
Mostow EN, Neckel SL, Oberhelman L, et al.: Complete remissions in psoralen and UV-A (PUVA)-refractory mycosis fungoides-type cutaneous T-cell lymphoma with combined interferon alfa and PUVA. Arch Dermatol 1993, 129:747–752.
Rupoli S, Barulli S, Guiducci B, et al.: Low dose interferon-alpha2b combined with PUVA is an effective treatment of early stage mycosis fungoides: results of a multicenter study. Cutaneous-T Cell Lymphoma Multicenter Study Group. Haematologica 1999, 84:809–813.
Wollina U, Liebold K, Kaatz M, et al.: Survival of patients with cutaneous T-cell lymphoma after treatment with extracorporeal photochemotherapy. Oncol Rep 2000, 7:1197–1201.
Saleh MN, LeMaistre CF, Kuzel TM, et al.: Antitumor activity of DAB389IL-2 fusion toxin in mycosis fungoides. J Am Acad Dermatol 1998, 39:63–73. This is an important study detailing current use of deneleukin diftitox in mycosis fungoides.
LeMaistre CF, Saleh MN, Kuzel TM, et al.: Phase I trial of a ligand fusion-protein (DAB389IL-2) in lymphomas expressing the receptor for interleukin-2. Blood 1998, 91:399–405. This is a second critical study detailing the use of deneleukin diftitox in mycosis fungoides.
Foss FM, Borkowski TA, Gilliom M, et al.: Chimeric fusion protein toxin DAB486IL-2 in advanced mycosis fungoides and the Sézary syndrome: correlation of activity and interleukin-2 receptor expression in a phase II study. Blood 1994, 84:1765–1774.
Heald P: The treatment of cutaneous T-cell lymphoma with a novel retinoid. Clin Lymphoma 2000, 1:545–549.
Foss FM, Ihde DC, Linnoila IR, et al.: Phase II trial of fludarabine phosphate and interferon alfa-2a in advanced mycosis fungoides/Sézary syndrome. J Clin Oncol 1994, 12:2051–2059.
Grozea PN, Jones SE, McKelvey EM, et al.: Combination chemotherapy for mycosis fungoides: a Southwest Oncology Group study. Cancer Treat Rep 1979, 63:647–653.
Kaye FJ, Bunn PA, Steinberg SM, et al.: A randomized trial comparing combination electron-beam radiation and chemotherapy with topical therapy in the initial treatment of mycosis fungoides. N Engl J Med 1989, 321:1784–1790.
Shustik C, Mick R, Silver R, et al.: Treatment of early chronic lymphocytic leukemia: intermittent chlorambucil versus observation. Hematol Oncol 1988, 6:7–12.
Hoppe RT: Total skin electron beam therapy in the management of mycosis fungoides. Front Radiat Ther Oncol 1991, 25:80–89.
Hoppe RT: The management of mycosis fungoides at Stanford—standard and innovative treatment programmes. Leukemia 1991, 5(suppl):46–48.